INTRODUCTION
Neuroleptic malignant syndrome (NMS) is a rare, lifethreatening idiosyncratic reaction secondary to antipsychotic medication. NMS is characterized by muscular rigidity, fever, autonomic instability, and an altered level of consciousness and it is usually accompanied by rhabdomyolysis. This syndrome is supposed to result from an excessively rapid blockade of postsynaptic dopamine receptors (1, 2) . Although the primary etiological factor is the initiation or elevation in the dose of antidopaminergic agents, there have been reports, albeit rarely, that NMS can be caused by the use of selective serotonin reuptake inhibitors (SSRIs), venlafaxine, and lithium (3).
It is well known that severe hyponatremia can cause neurologic complications such as stupor, seizures, and even coma. Hyponatremia frequently develops in elderly patients and also psychiatric patients. Hyponatremia associated with neuroleptic malignant syndrome has been described as a syndrome of inappropriate secretion of antidiuretic hormone (4).
We have reported an elder patient with recurrent depression taking venlafaxine and olanzapine therapy who developed overt NMS following the hyponatremia. 
DISCUSSION
We presented a case of neuroleptic malignant syndrome secondary to antipsychotic dose escalation by hyponatremia. The development of hyponatremia has facilitated because of the patient is elderly and use of venlafaxine.
Older age appears to be the major risk factor for SSRIs; antidepressant-associated hyponatremia in elderly patients (9) . In a prospective study, the incidence of hyponatremia was 17.2% in patients aged >65 years with venlafaxine therapy (10) . This patient has been used venlafaxine and low dose olanzapine last six years. NMS might develop after increase the dose of olanzapine in this patient.
In our case, symptoms of hyponatremia included nausea and disorientation, which seemed to be relatively modest. However, his serum sodium level was 121 mEq/L which could lead to severe symptoms. Appropriate treatments were conducted at an early stage, but patient might have developed NMS after hyponatremia treatment.
Perhaps, SNRI and antipsychotic medication may have triggered NMS in this case. Dehydration is another risk factor for NMS. However, this patient had hyponatremia rather than dehydration
In conclusion, this report shows that NMS may occur following antidepressant-induced hyponatremia; therefore the combination of antipsychotic and antidepressant needed to be used with caution in patients with depression.
The changes in metabolism in an elderly patient with depression may lead to life-threatening problems.
Clinicians should inform their patients about the use of drugs, drug dose, and side effects.
